These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 25127922

  • 1. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
    Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R.
    J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
    [Abstract] [Full Text] [Related]

  • 2. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
    Al-Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D.
    Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 4. The Association between Aminoglycoside Exposure and Ototoxicity in Children with Cystic Fibrosis.
    Yilmaz Yegit C, Ergenekon P, Yanaz M, Ozturk Akar N, Toktas Yavuz F, Molla Kafi H, Çollak A, Bal N, Gedik Toker Ö, Meral Ö, Ataş A, Çetin Kara H, Ayhan Y, Guliyeva A, Yuksel Kalyoncu M, Selçuk Balcı M, Karabulut Ş, Taştan G, Uzunoglu B, Karasu N, Oruc Y, Acar M, Yumuşakhuylu AC, Dogan R, Gozen Tan ED, Ata P, Kılınç Sakallı AA, Girit S, Cakir E, Gokdemir Y, Erdem Eralp E, Ciprut A, Karakoc F, Karadag B.
    Respiration; 2024 Sep 19; ():1-10. PubMed ID: 39299224
    [Abstract] [Full Text] [Related]

  • 5. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
    Geyer LB, Menna Barreto SS, Weigert LL, Teixeira AR.
    Braz J Otorhinolaryngol; 2015 Sep 19; 81(6):589-97. PubMed ID: 26480907
    [Abstract] [Full Text] [Related]

  • 6. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA.
    J Cyst Fibros; 2021 Mar 19; 20(2):288-294. PubMed ID: 33341407
    [Abstract] [Full Text] [Related]

  • 7. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.
    Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N.
    Arch Otolaryngol Head Neck Surg; 2002 Feb 19; 128(2):150-5. PubMed ID: 11843723
    [Abstract] [Full Text] [Related]

  • 8. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR, Kraemer DF, Winter C, Neuwelt EA.
    J Clin Oncol; 2007 Apr 01; 25(10):1190-5. PubMed ID: 17401008
    [Abstract] [Full Text] [Related]

  • 9. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
    Garinis A, Gleser M, Johns A, Larsen E, Vachhani J.
    J Cyst Fibros; 2021 Mar 01; 20(2):278-283. PubMed ID: 32713806
    [Abstract] [Full Text] [Related]

  • 10. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G.
    Int J Pediatr Otorhinolaryngol; 2001 May 31; 59(1):47-57. PubMed ID: 11376818
    [Abstract] [Full Text] [Related]

  • 11. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
    Lisowska G, Namysłowski G, Hajduk A, Polok A, Tomaszewska R, Misiołek M.
    Otolaryngol Pol; 2006 May 31; 60(3):415-20. PubMed ID: 16989457
    [Abstract] [Full Text] [Related]

  • 12. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
    Garinis AC, Keefe DH, Hunter LL, Fitzpatrick DF, Putterman DB, McMillan GP, Gold JA, Feeney MP.
    Ear Hear; 2018 May 31; 39(1):69-84. PubMed ID: 28708814
    [Abstract] [Full Text] [Related]

  • 13. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
    Md Daud MK, Mohamadl H, Haron A, Rahman NA.
    B-ENT; 2014 May 31; 10(1):53-8. PubMed ID: 24765829
    [Abstract] [Full Text] [Related]

  • 14. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI, Bosso J, Randolph L.
    Am J Dis Child; 1989 Nov 31; 143(11):1328-32. PubMed ID: 2816859
    [Abstract] [Full Text] [Related]

  • 15. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.
    Farzal Z, Kou YF, St John R, Shah GB, Mitchell RB.
    Laryngoscope; 2016 Jan 31; 126(1):228-35. PubMed ID: 26152803
    [Abstract] [Full Text] [Related]

  • 16. Otoacoustic emissions--an approach for monitoring aminoglycoside induced ototoxicity in children.
    Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, Douniadakis D.
    Int J Pediatr Otorhinolaryngol; 1999 Nov 05; 50(3):177-84. PubMed ID: 10595663
    [Abstract] [Full Text] [Related]

  • 17. Extended High-Frequency Audiometry for Ototoxicity Monitoring: A Longitudinal Evaluation of Drug-Resistant Tuberculosis Treatment.
    Stevenson LJ, Biagio-de Jager L, Graham MA, Swanepoel W.
    Am J Audiol; 2023 Mar 05; 32(1):70-80. PubMed ID: 36490390
    [Abstract] [Full Text] [Related]

  • 18. Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.
    Caumo DTM, Geyer LB, Teixeira AR, Barreto SSM.
    Braz J Otorhinolaryngol; 2017 Mar 05; 83(4):464-474. PubMed ID: 27894912
    [Abstract] [Full Text] [Related]

  • 19. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
    Zettner EM, Gleser MA.
    Otolaryngol Head Neck Surg; 2018 Nov 05; 159(5):887-894. PubMed ID: 29914288
    [Abstract] [Full Text] [Related]

  • 20. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, Smyth A.
    Antimicrob Agents Chemother; 2006 Jul 05; 50(7):2293-9. PubMed ID: 16801404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.